In his blog, Tim Behrendt, our VP HR and Internal Communications, describes the lasting impacts that the pandemic has had on the way that we work and how the “The Great Resignation” can potentially evolve to something that we can call “The Great Reinvestment.” What’s next for companies to consider in their policies and recruitment efforts to support talent?
Embracing diversity of thinking, background, and culture where everyone is acknowledged as a valuable contributor
The Challenges and Successes of Building Company Culture The five core values on which Affimed stands
To deliver life-changing medicines, we have the courage to be imaginative in our approach and we are convinced that change must be our constant.
How a dream-ending sports injury prompted our Chief Medical Officer to study medicine and take on cancer as his biggest opponent
Courage can come in many forms and inspire your community to enact positive change
Arndt Schottelius, Chief Scientific Officer of Affimed, shares how his personal experience fuels the company’s vision to improve therapeutics for cancer
Long known for their crucial role in fighting human pathogens, natural killer (NK) cells have been recognized for other exciting tasks in the past years. Especially their role in fighting cancer has gained a lot of interest. The stakes are high: A breakthrough in innate immune-oncology is expected to be a quantum leap in cancer therapy.
Activating the innate immune system to revolutionize the treatment landscape for patients with CD30-positive lymphomas and EGFR- expressing solid tumors
Activating the innate immune system to revolutionize the treatment landscape for patients with CD30-positive lymphomas
Harnessing the power of the immune system has the potential to change the future of cancer treatment.
Harnessing the power of the immune system has the potential to change the future of cancer treatment.
Like all illnesses and conditions – there is no one-size-fits-all approach to fighting cancer.
CD=cluster of differentiation; EGFR=epidermal growth factor receptor.